ArticleProceedings of the National Academy of Sciences of the United States of America2003
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 127 citations in OpenAlex.
- Trial
- Progress and prospects in HIV/AIDS pathogenicity research using rhesus macaque models: from SHIV model development to neutralizing antibody induction.The Journal of veterinary medical science · 2026Review
- Broadly neutralizing antibodies, nonneutralizing antibodies and broadly effector antibodies to prevent HIV transmission?AIDS (London, England) · 2025Article
- HIV-1 neutralizing antibodies provide sterilizing immunity by blocking infection of the first cells.Cell reports. Medicine · 2023Article
- Vaccine Design Informed by Virus-Induced Immunity.Viral immunology · 2020Review
- Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.Retrovirology · 2019Article
- Revisiting the 'sterilising cure' terminology: a call for more patient-centred perspectives on HIV cure-related research.Journal of virus eradication · 2019Article
- Antibody-dependent cellular cytotoxicity in HIV infection.AIDS (London, England) · 2018Review
- A Bistable Switch in Virus Dynamics Can Explain the Differences in Disease Outcome Following SIV Infections in Rhesus Macaques.Frontiers in microbiology · 2018Article
- Article
- Use of broadly neutralizing antibodies for HIV-1 prevention.Immunological reviews · 2017Review
- Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Frontiers in immunology · 2017Review
- Survivors Remorse: antibody-mediated protection against HIV-1.Immunological reviews · 2017Review
- Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.AIDS (London, England) · 2016Article
- Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization.Frontiers in microbiology · 2016Review
- Review
- Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.Proceedings of the National Academy of Sciences of the United States of America · 2014Review
- Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.Journal of virology · 2014Article
- Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Passive transfer of high-titered antiviral neutralizing IgG, known to confer sterilizing immunity in pig-tailed monkeys, has been used to determine how soon after virus exposure neutralizing antibodies (NAbs) must be present to block a simian immunodeficiency virus (SIV)/HIV chimeric virus infection. Sterilizing protection was achieved in three of four macaques receiving neutralizing IgG 6 h after intravenous SIV/HIV chimeric virus inoculation as monitored by PCR analyses of and attempted virus isolations from plasma, peripheral blood mononuclear cell, and lymph node specimens. In the fourth animal, the production of progeny virus was suppressed for >4 weeks. A delay in transferring NAbs until 24 h after virus challenge resulted in infection in two of two monkeys. These results suggest that even if a vaccine capable of eliciting broadly reactive NAbs against primary HIV-1 were at hand, the Abs generated must remain at, or rapidly achieve, high levels within a relatively short period after exposure to virus to prevent the establishment of a primate lentivirus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.